The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1669
February 6, 2023
View Complete Issue         Table of Contents 2019 
Dupilumab (Dupixent) for Eosinophilic Esophagitis and Prurigo Nodularis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Dupilumab (Dupixent) for Eosinophilic Esophagitis and Prurigo Nodularis
February 6, 2023 (Issue: 1669)
The FDA has approved the subcutaneously injected interleukin (IL)-4 receptor alpha antagonist dupilumab (Dupixent – Sanofi/Regeneron) for treatment of eosinophilic esophagitis (EoE) in patients ≥12 years old who weigh ≥40 kg and treatment...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Dupilumab (Dupixent) for Eosinophilic Esophagitis and Prurigo Nodularis
Article code: 1669b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.